As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, ...

Another recent federal study, published in the journal JAMA Pediatrics in February, showed approximately 1.01 million ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Five years ago on Tuesday, the World Health Organization declared COVID-19 a global pandemic, and the impact of the virus and ...

The federal government has cancelled a deal with vaccine maker Novavax to manufacture COVID-19 vaccine in Montreal, the company said in a filing with the U.S. securities regulator.

Novavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker.

Breakthrough Adjuvant AB-801 Secures“Bioprocessing Excellence in Taiwan” HonorTAIPEI, Taiwan, March 13, 2025 (GLOBE NEWSWIRE) ...

Novavax also earned global approvals for and commercialized its first vaccine ever for COVID-19, ramping up quickly to meet the demands of the global pandemic. Dr. Young helped to guide the ...